☰

Hao Xie, MD, PhD - Publications

Affiliations: 
Oncology Mayo Clinic at Rochester 
 2004-2009 Chemistry Princeton University, Princeton, NJ 
 2009-2014 Medicine Cleveland Clinic Lerner College of Medicine, Cleveland, OH, United States 
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Liu J, Xie H. BRAF Non-V600 Mutations in Metastatic Colorectal Cancer. Cancers. 15. PMID 37760573 DOI: 10.3390/cancers15184604  0.542
2023 Alem D, Yang X, Beato F, Sarcar B, Tassielli AF, Dai R, Hogenson TL, Park MA, Jiang K, Cai J, Yuan Y, Fernandez-Zapico ME, Tan AC, Fleming JB, Xie H. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer. Molecular Carcinogenesis. PMID 37042566 DOI: 10.1002/mc.23543  0.547
2023 Liu J, Wang X, Sahin IH, Imanirad I, Felder SI, Kim RD, Xie H. Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology. PMID 36606664 DOI: 10.1097/COC.0000000000000972  0.541
2022 Bian Y, Alem D, Beato F, Hogenson TL, Yang X, Jiang K, Cai J, Ma WW, Fernandez-Zapico M, Tan AC, Lawrence NJ, Fleming JB, Yuan Y, Xie H. Development of SOS1 Inhibitor-Based Degraders to Target -Mutant Colorectal Cancer. Journal of Medicinal Chemistry. PMID 36459180 DOI: 10.1021/acs.jmedchem.2c01300  0.542
2021 Xie H, Liu J, Alem Glison DM, Fleming JB. The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-Tumor Therapy. 2: 511-521. PMID 36046114 DOI: 10.37349/etat.2021.00061  0.525
2020 Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. The Oncologist. PMID 32663355 DOI: 10.1634/Theoncologist.2020-0086  0.564
2020 Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology. PMID 32349022 DOI: 10.1097/Coc.0000000000000708  0.572
2019 Xie H, Liu J, Yadav S, Keutgen X, Hobday T, Strosberg JR, Halfdanarson T. The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms. Neuroendocrinology. PMID 31121586 DOI: 10.1159/000501126  0.589
2019 Xie H, Yadav S, Keutgen X, Hobday TJ, Strosberg JR, Halfdanarson TR. The role of perioperative systemic therapy in localized pancreatic neuroendocrine tumor. Journal of Clinical Oncology. 37: 322-322. DOI: 10.1200/Jco.2019.37.4_Suppl.322  0.318
2019 Xie H, Hogenson TL, Horn IP, Almada L, Marks D, Koenig A, Tolosa E, Barrett MT, Boyum JH, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Yin J, Petersen GM, Revzin A, et al. Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients. Journal of Clinical Oncology. 37: 3101-3101. DOI: 10.1200/Jco.2019.37.15_Suppl.3101  0.307
2018 Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, et al. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology. PMID 30418178 DOI: 10.1097/Coc.0000000000000492  0.305
2015 Liu G, Lin J, Xie H, Shen B, Stocchi L, Liu X. Histomorphological features and prognosis of colitis-associated colorectal cancer in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. 1-8. PMID 26061393 DOI: 10.3109/00365521.2015.1052094  0.311
2015 Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflammatory Bowel Diseases. 21: 378-84. PMID 25569733 DOI: 10.1097/Mib.0000000000000286  0.311
2013 Lewis B, Lin J, Wu X, Xie H, Shen B, Lai K, Manilich E, Liu X. Crohn's disease-like reaction predicts favorable prognosis in colitis-associated colorectal cancer. Inflammatory Bowel Diseases. 19: 2190-8. PMID 23917251 DOI: 10.1097/Mib.0B013E31829E13E1  0.334
2013 Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 61: 148-55. PMID 23124118 DOI: 10.1369/0022155412468137  0.304
2013 Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 119: 173-81. PMID 22736490 DOI: 10.1002/Cncr.27715  0.312
2012 Dahiya S, Xie H, Hill BT, Peereboom D, Stevens GH, Murphy E, Chao S, Suh J, Ahluwalia MS. Primary Central Nervous System Lymphoma in Elderly Patients: Clinical Outcomes and Prognosis Blood. 120: 5083-5083. DOI: 10.1182/Blood.V120.21.5083.5083  0.304
2011 Xie H, Sammis GM, Flamme EM, Kraml CM, Sorensen EJ. The catalytic asymmetric Diels-Alder reactions and post-cycloaddition reductive transpositions of 1-hydrazinodienes. Chemistry (Weinheim An Der Bergstrasse, Germany). 17: 11131-4. PMID 21898626 DOI: 10.1002/Chem.201102394  0.641
2005 Sammis GM, Flamme EM, Xie H, Ho DM, Sorensen EJ. Design, synthesis, and reactivity of 1-hydrazinodienes for use in organic synthesis. Journal of the American Chemical Society. 127: 8612-3. PMID 15954764 DOI: 10.1021/Ja052383C  0.639
Show low-probability matches.